Association Between Substantia Nigra Degeneration and Functional Outcome in Patients with Basal Ganglia Infarction

Overview

Journal Eur J Neurol

Publisher Wiley

Specialty Neurology

Date 2023 Oct 30

PMID 37903090

Authors

Hyungwoo Lee

Kijeong Lee

Young Dae Kim

Hyo Suk Nam

Hye Sun Lee

Sunghee Cho

Ji Hoe Heo

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Cerebral infarction in the basal ganglia may cause secondary and delayed neuronal degeneration in the substantia nigra (SN). However, the clinical significance of SN degeneration remains poorly understood.

Methods: This retrospective observational study included patients with acute ischemic stroke in the basal ganglia on initial diffusion-weighted imaging who underwent follow-up diffusion-weighted imaging between 4 and 30 days after symptom onset. SN degeneration was defined as a hyperintensity lesion in the SN observed on diffusion-weighted imaging. We compared functional outcomes at 3 months between patients with and without SN degeneration. A poor outcome was defined as a score of 3-6 (functional dependence or death) on the modified Rankin Scale.

Results: Of 350 patients with basal ganglia infarction (median age = 74.0 years, 53.7% male), 125 (35.7%) had SN degeneration. The proportion of functional dependence or death was 79.2% (99/125 patients) in patients with SN degeneration, which was significantly higher than that in those without SN degeneration (56.4%, 127/225 patients, p < 0.001). SN degeneration was more frequent in patients with functional dependence or death (99/226 patients, 43.8%) than in those with functional independence (26/124 patients, 21.0%, p < 0.001). Multivariable logistic regression analysis showed a significant association between SN degeneration and functional dependence or death (odds ratio = 2.91, 95% confidence interval = 1.17-7.21, p = 0.021).

Conclusions: The study showed that patients with degeneration of SN were associated with functional dependence or death at 3 months, suggesting that secondary degeneration is a predictor of poor stroke outcomes and a potential therapeutic target.

Citing Articles

Ischemic Conditioning Promotes Transneuronal Survival and Stroke Recovery via CD36-Mediated Efferocytosis.

Ju H, Kim I, Pavlova I, Mu S, Park K, Minkler J Circ Res. 2025; 136(5):e34-e51.

PMID: 39886760 PMC: 11867857. DOI: 10.1161/CIRCRESAHA.124.325428.

Evaluating iron deposition in gray matter nuclei of patients with acute ischemic stroke using quantitative susceptibility mapping.

Zhou L, Yang J, Zhang W, Han L, Zhou S, Zheng C Front Neurol. 2025; 15:1518911.

PMID: 39744117 PMC: 11688647. DOI: 10.3389/fneur.2024.1518911.

Association between substantia nigra degeneration and functional outcome in patients with basal ganglia infarction.

Lee H, Lee K, Kim Y, Nam H, Lee H, Cho S Eur J Neurol. 2023; 31(2):e16111.

PMID: 37903090 PMC: 10841447. DOI: 10.1111/ene.16111.

References

Kuchcinski G, Munsch F, Lopes R, Bigourdan A, Su J, Sagnier S . Thalamic alterations remote to infarct appear as focal iron accumulation and impact clinical outcome. Brain. 2017; 140(7):1932-1946. PMC: 6248443. DOI: 10.1093/brain/awx114. View

Nakane M, Tamura A, Miyasaka N, Nagaoka T, Kuroiwa T . Astrocytic swelling in the ipsilateral substantia nigra after occlusion of the middle cerebral artery in rats. AJNR Am J Neuroradiol. 2001; 22(4):660-3. PMC: 7976031. View

Furukawa K, Shima A, Kambe D, Nishida A, Wada I, Sakamaki H . Motor Progression and Nigrostriatal Neurodegeneration in Parkinson Disease. Ann Neurol. 2022; 92(1):110-121. DOI: 10.1002/ana.26373. View

FORNO L . Reaction of the substantia nigra to massive basal ganglia infarction. Acta Neuropathol. 1983; 62(1-2):96-102. DOI: 10.1007/BF00684925. View

Park K, Ju H, Kim I, Cave J, Guo Y, Wang W . Delayed Infiltration of Peripheral Monocyte Contributes to Phagocytosis and Transneuronal Degeneration in Chronic Stroke. Stroke. 2022; 53(7):2377-2388. PMC: 9245247. DOI: 10.1161/STROKEAHA.122.038701. View

Zhang J, Zhang Y, Xing S, Liang Z, Zeng J . Secondary neurodegeneration in remote regions after focal cerebral infarction: a new target for stroke management?. Stroke. 2012; 43(6):1700-5. DOI: 10.1161/STROKEAHA.111.632448. View

Ladwig A, Rogall R, Hucklenbroich J, Willuweit A, Schoeneck M, Langen K . Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke. J Neuroimmune Pharmacol. 2018; 14(2):295-311. DOI: 10.1007/s11481-018-9826-1. View

Carmichael S, Tatsukawa K, Katsman D, Tsuyuguchi N, Kornblum H . Evolution of diaschisis in a focal stroke model. Stroke. 2004; 35(3):758-63. DOI: 10.1161/01.STR.0000117235.11156.55. View

Linck P, Kuchcinski G, Munsch F, Griffier R, Lopes R, Okubo G . Neurodegeneration of the Substantia Nigra after Ipsilateral Infarct: MRI R2* Mapping and Relationship to Clinical Outcome. Radiology. 2019; 291(2):438-448. DOI: 10.1148/radiol.2019182126. View

10.

Lee K, Lee H, Kim Y, Nam H, Lee H, Yoo J . Association of Substantia Nigra Degeneration with Poor Neurological Recovery in Basal Ganglia Infarctions. J Stroke. 2022; 25(1):169-172. PMC: 9911844. DOI: 10.5853/jos.2022.02145. View

11.

Tamura A, Kirino T, Sano K, Takagi K, Oka H . Atrophy of the ipsilateral substantia nigra following middle cerebral artery occlusion in the rat. Brain Res. 1990; 510(1):154-7. DOI: 10.1016/0006-8993(90)90744-v. View

12.

Nakajima M, Inatomi Y, Okigawa T, Yonehara T, Hirano T . Secondary signal change and an apparent diffusion coefficient decrease of the substantia nigra after striatal infarction. Stroke. 2012; 44(1):213-6. PMC: 4080835. DOI: 10.1161/STROKEAHA.112.673020. View

13.

Weisscher N, Vermeulen M, Roos Y, de Haan R . What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2?. J Neurol. 2008; 255(6):867-74. DOI: 10.1007/s00415-008-0796-8. View

14.

Lee K, Kim E, Song D, Kim Y, Nam H, Lee H . Lenticulostriate Artery Involvement is Predictive of Poor Outcomes in Superficial Middle Cerebral Artery Territory Infarction. Yonsei Med J. 2016; 58(1):123-130. PMC: 5122627. DOI: 10.3349/ymj.2017.58.1.123. View

15.

Sabogal A, Arango C, Cardona G, Cespedes A . Atorvastatin protects GABAergic and dopaminergic neurons in the nigrostriatal system in an experimental rat model of transient focal cerebral ischemia. Biomedica. 2014; 34(2):207-17. DOI: 10.1590/S0120-41572014000200007. View

16.

Nakajima M, Hirano T, Terasaki T, Uchino M . Signal change of the substantia nigra on diffusion-weighted imaging following striatal infarction. Intern Med. 2010; 49(1):65-8. DOI: 10.2169/internalmedicine.49.2694. View

17.

Lee H, Lee K, Kim Y, Nam H, Lee H, Cho S . Association between substantia nigra degeneration and functional outcome in patients with basal ganglia infarction. Eur J Neurol. 2023; 31(2):e16111. PMC: 10841447. DOI: 10.1111/ene.16111. View

18.

Nakane M, Teraoka A, Asato R, Tamura A . Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke. 1992; 23(3):328-32. DOI: 10.1161/01.str.23.3.328. View

19.

Nakane M, Tamura A, Sasaki Y, Teraoka A . MRI of secondary changes in the thalamus following a cerebral infarct. Neuroradiology. 2002; 44(11):915-20. DOI: 10.1007/s00234-002-0846-3. View

20.

von Olnhausen O, Thoren M, Von Vogelsang A, Svensson M, Schechtmann G . Predictive factors for decompressive hemicraniectomy in malignant middle cerebral artery infarction. Acta Neurochir (Wien). 2016; 158(5):865-72. DOI: 10.1007/s00701-016-2749-9. View